Safety and cost analysis of early discharge following percutaneous coronary intervention for acute coronary syndrome in patients with diabetes mellitus

Shihong Li*, Zhizhong Li*, Xuejian Hou, Junping Sun, Lihui Kang, Yutong Cheng, Ying Tao, Zhao Li, Xuanzu Chen, Donghua Zhang, Xianliang Yan, Su Wang, Yulong Gao, Qian Wang, Yun Lin, Chengqian Yin, Jingmei Zhang, Yun Gao, Ji Huang, Xiangyu Wu, Nan Li, Wang Su, Honghong Liu and Tao Sun

Abstract
Objective: To evaluate the safety and cost of early discharge compared with ordinary discharge in patients with diabetes mellitus (DM) following percutaneous coronary intervention (PCI) for acute coronary syndrome.
Methods: We performed a retrospective analysis of prospectively collected data from 474 patients with DM who were discharged from hospital following PCI at a regional center between 2012 and 2015.
Results: A total of 192 patients (40.5%) were included in the early discharge group and 282 patients (59.5%) were included in the ordinary group. Mortality and morbidity after PCI were recorded. Kaplan–Meier analysis showed similar prognosis between the two groups at 30 days and at 1 year after discharge. However, hospitalization expenses for the regular discharge group were significantly higher than those of the early discharge group (RMB65,750 vs. RMB50,983).

Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, Beijing, China

*These authors contributed equally to this work

Corresponding author:
Tao Sun, Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, No. 2 Anzhen Rd, Beijing, 100029, China.
Email: taomayoclinic@sina.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Conclusion: Our findings demonstrate that early discharge of patients with DM following PCI for acute coronary syndrome is safe compared with ordinary discharge, and may reduce hospitalization costs.

Keywords
Diabetes mellitus, safety and cost, acute coronary syndrome, percutaneous coronary intervention, early discharge, hospitalization

Date received: 27 August 2018; accepted: 18 March 2019

Introduction
Diabetes mellitus (DM) has become a twenty-first century pandemic, with a marked rise in prevalence in developed and developing countries. A recent survey of the worldwide prevalence of DM reported a rate of 6.4% in 2010, representing 285 million adults, with an expected rise to 7.7% by 2030 (439 million adults). In a landmark nationwide study in China in 2010, the overall prevalence of DM was reported as 11.6% in the general Chinese adult population. DM is a multisystem disorder and a recognized risk factor for coronary artery disease (CAD). Complications associated with DM represent a significant health burden in China.

The number of patients requiring percutaneous coronary intervention (PCI) for CAD is increasing year by year, and the health economics of this procedure represent an important issue. Hospitalization days and costs are the key indicators of hospital medical burden. Controlling the rapid increase of hospital expenses is of significance to patients, families, governments, and medical insurance companies. Previous studies have shown that for certain types of coronary heart disease and in some Chinese hospitals, there is a trend towards declining hospitalization time, while other hospital-based single-center studies have shown that the cost of hospitalization for coronary heart disease has increased. Among these somewhat contradictory findings, however, there remains a lack of research on the relative safe hospitalization time of PCI for patients with DM and coronary heart disease in a representative large sample population, as well as the relationship with hospitalization costs.

In this study, 474 patients with DM who underwent PCI for the treatment of ACS from 2012 to 2015 were retrospectively evaluated at 30 days of follow-up after discharge to determine the cost and number of days of hospitalization. We sought to clarify whether early discharge following PCI in this patient population is safe compared with ordinary discharge, and whether early discharge can reduce costs and thus contribute to the recognized benefits of the PCI procedure.

Methods
Study population
The hospital electronic case system was used to identify hospitalized patients with DM who underwent PCI at Beijing An Zhen Hospital from January 2012 to June 2015.

Inclusion criteria: (1) age ≥45 years; (2) PCI; (3) successfully placed with DES; (4) with unstable angina pectoris (UAP), non-
ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) as revascularization indications; (5) patients with a history of diabetes, insulin or hypoglycemic treatment at admission, and new-onset diabetes during hospitalization; (6) obtaining informed consent.

Exclusion criteria: (1) malignant tumor; (2) liver and kidney disease; (3) infection; (4) blood and immune system diseases; (5) type 1 diabetes; (6) rheumatic valvular heart disease and cardiomyopathy history; (7) Patients with incomplete data, patients who missed their visit within 1 year after receiving PCI.

Information collection and indicator definition

A retrospective analysis of prospective data was performed. Demographic, clinical, laboratory, coronary angiography, and coronary stenting data were retrieved for all enrolled patients, as well as records of medication administered during discharge and follow-up. Specifically, the following information was collected: sex, age, weight, height, blood pressure, symptoms at admission, cardiac function, and biochemical indicators. Medical history of diabetes, hypertension, dyslipidemia, smoking status, diabetes history, receipt of insulin treatment, non-fatal myocardial infarction (MI), non-fatal stroke, medications, and fasting plasma biochemical indicators before and after revascularization were also collected.

Diagnosis of DM was based on the 2014 American Diabetes Association (ADA) guidelines, and dyslipidemia assessment was based on the 2013 diagnostic criteria of the European Regulations on Dyslipidemia. Diagnosis of hypertension was based on the American Diabetes Prevention and Treatment Guidelines (JNC7), and patients with a history of essential hypertension were diagnosed with hypertension if they were using antihypertensive drugs at enrollment. Patients who had smoked for more than 1 year before admission or who had stopped smoking for less than 1 year were classified as smokers.

Study design

This was a retrospective observational cohort study. The primary data source was the local coronary artery disease database in the hospital electronic case system, which contains information on every PCI procedure performed at our hospital, including prospectively entered baseline demographics, procedural details, and clinical presentation.

Outcome measures

The main outcome measure was all-cause mortality at 30 days and at 1 year of post-discharge follow-up. Discharge minor events including bleeding, infection, and fever were collected, as was the incidence of major adverse cardiac and cerebrovascular events (MACCE) observed at 30 days and at 1 year of follow-up. Clinical follow-up data were obtained by independent follow-up teams during telephone and outpatient visits.

Length of hospital stay

Patients were classified by length of hospital stay into (1) an early discharge group, consisting of patients discharged from hospital within 6 days following PCI; and (2) an ordinary discharge group, consisting of all other patients.

Statistical analysis

Continuous variable distributions were assessed for normality using the Kolmogorov–Smirnov test. Continuous variable data with a normal distribution
were expressed as the mean (standard deviation), and data with skewed distributions were expressed as medians (interquartile range [IQR]). Differences between normally distributed continuous variables were analyzed using an unpaired test. The Mann–Whitney U test was used for continuous variables with a skewed distribution. Groups were compared using a chi–squared test. Multiple binary logistic regression analyses were performed to identify independent variables associated with early discharge. The cumulative incidence of cardiovascular events was calculated using the Kaplan–Meier method and compared using a log-rank test. A two-sided value of \( p < 0.05 \) was considered significant. All analyses were performed using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, IL, USA).

**Ethics approval and consent to participate**

Ethical approval was obtained from the Ethics Committee of Beijing An Zhen Hospital Capital Medical University, and all participants provided signed informed consent prior to participation.

**Results**

**Patient disposition**

All 474 patients (60.0±8.0 years old, 68.6% male) who underwent PCI at our center and survived to hospital discharge were included in the study. There were 192 patients (40.5%) in the early discharge group and 282 patients (59.5%) in the regular discharge group. The median and IQR of length of hospital stay was 6 (3–6) days (mean of 4.5 days) in the early discharge group compared with 9 (6–11) days (mean of 8.5 days) in the ordinary discharge group.

There were significant differences in hospitalization costs, left ventricular ejection

| Table 1. Baseline characteristics of enrolled patients |
|---------------------------------|
| Age (years) | 60±8 |
| Men/women | 325/149 |
| Height (cm) | 167±23 |
| BMI Median (Q1,Q3) | 26.6(24.4,28.8) |
| LOS Median (Q1,Q3) | 6(5,8) |
| Expense in hospital (RMB) | 59012±26980 |
| HbA1C (%) | 7.3±2.4 |
| UAP/NSTEMI/STEMI | 389/19/66 |
| Thrombosis history | 45 |
| Pectoris history | 407 |
| Pre-PCI history | 98 |
| Pre-CABG | 16 |
| Hypertension history | 352 |
| SBP (mmHg) | 130±18 |
| DBP (mmHg) | 76±10 |
| Anti-hypertension | 262 |
| Arrhythmia history | 15 |
| Heart failure | 2 |
| CVD history | 71 |
| Peripheral disease | 15 |
| Ex-smoker | 169 |
| HR (time/minute) | 65±19 |
| ALT median (Q1,Q3) | 22(14.5,32) |
| AST median (Q1,Q3) | 20(16, 25) |
| Cr median (Q1,Q3) | 97(79, 115) |
| UA | 290±134 |
| Glucose (mmol/L) | 7.8±5.9 |
| TG (mmol/L) | 2.04±1.68 |
| CRP median (Q1,Q3) | 1.50(0.67, 3.66) |
| cTnI median (Q1,Q3) | 0.01(0, 0.07) |
| Pro-BNP median (Q1,Q3) | 27(10, 62) |
| WBC (G/L) | 6.78±2.13 |
| RBC (T/L) | 4.54±2.05 |
| HGB (g/L) | 136±32 |
| PLT (G/L) | 206±66 |
| Discharge minor events (n,% ) | 30(6.3) |
| 30-day events (n,% ) | 10(2.1) |
| TRI (n, %) | 57(12.0) |
| Triple vessels (n,% ) | 103(21.7) |
| Double vessels (n,% ) | 169(35.7) |
| CTO (n,% ) | 89(18.8) |

Values are mean±SD or %

BMI, body mass index; LOS, length of stay; HbA1C, hemoglobin A1c; UAP, unstable angina pectoris; NSTEMI, non-ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; SBP, systolic pressure; DBP, diastolic blood pressure; CVD, cardiovascular disease; HR, heart rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, creatinine; UA, uric acid; TG, triglyceride; CRP, C-reactive protein; cTnI, sensitive cardiac troponin T; BNP, brain natriuretic peptide; WBC, white blood cell; RBS, red blood cell; HGB, hemoglobin; PLT, platelet; TRI, transfemoral coronary intervention; CTO, chronic total occlusion
Table 2. Clinical comparison between the early discharge group and ordinary discharge group.

|                        | Early discharge (<6 days n=192) | Ordinary discharge (>=6 days n=282) | P-value |
|------------------------|----------------------------------|-------------------------------------|---------|
| Age (years)            | 60±8.4                           | 60±8.2                              | 0.91    |
| Men/women              | 131/61                           | 194/88                              | 0.88    |
| BMI                    | 26±6.3                           | 27±7.5                              | 0.21    |
| Cost (RMB)             | 50983±16780                      | 65750±14950                        | <0.0001 |
| HbAC1 (%)              | 7.2±1.3                          | 7.5±1.4                             | 0.024   |
| UAP                    | 158/192                          | 231/282                             | 0.94    |
| NSTEMI                 | 7/192                            | 12/282                              |         |
| STEMI                  | 27/192                           | 39/282                              |         |
| SBP (mmHg)             | 129±15                           | 131±17                              | 0.45    |
| DSP (mmHg)             | 76±10                            | 76±9                                | 0.79    |
| LVEDD (mm)             | 39±18                            | 42±15                               | 0.08    |
| LVESD (mm)             | 24±14                            | 26±12                               | 0.10    |
| LVEF (%)               | 64±6                             | 62±7                                | 0.002   |
| HR beats/minute        | 64±20                            | 65±18                               | 0.56    |
| Cr (µmol/L)            | 101±36                           | 138±42                              | 0.18    |
| UA (µmol/L)            | 290±129                          | 289±130                             | 0.90    |
| HDL (mmol/L)           | 0.99±0.27                        | 0.92±0.27                           | 0.012   |
| TG (mmol/L)            | 1.94±1.67                        | 2.11±1.71                           | 0.26    |
| TC (mmol/L)            | 4.12±0.97                        | 4.01±1.04                           | 0.54    |
| LDL (mmol/L)           | 2.38±0.70                        | 2.37±0.86                           | 0.93    |
| CRP (mg/L)             | 1.25(0.54,2.80)                  | 1.73(0.76,4.41)                     | 0.013   |
| cTnl (µg/L)            | 0.01(0.009)                      | 0.03(0.009)                         | 0.04    |
| Pro-BNP (pg/mL)        | 23(8.61)                         | 29(11.62)                           | 0.06    |
| Glucose (mmol/L)       | 8.0±7.4                          | 7.6±4.9                             | 0.47    |
| 1 year FU events (n,%) | 18(9.38)                         | 30(10.64)                           | 0.65    |
| 30 days events (n, %)  | 6(3.13)                          | 4(1.42)                             | 0.21    |
| Discharge minor event (n, %) | 10(5.21) | 20(7.09)                             | 0.40    |
| CTO                    | 31(16.15)                        | 58(20.57)                           | 0.21    |
| LMS                    | 4(2.08)                          | 12(4.26)                            | 0.18    |
| Lesion length >=20 mm  | 6(3.13)                          | 22(7.80)                            | 0.027   |
| Double vessel          | 80(41.67)                        | 89(31.56)                           | 0.025   |
| Ex-smoker              | 63(32.8)                         | 106(37.59)                          | 0.28    |
| Denovol (y/n)          | 26/166                           | 32/250                              | 0.47    |
| In-stent restenosis (y/n) | 10/182       | 14/268                              | 0.90    |
| CABG (y/n)             | 1/192                            | 3/279                               | 0.51    |
| Heparin (y/n)          | 90/102                           | 146/136                             | 0.29    |
| Pre-CAD                | 171/192                          | 251/282                             | 0.98    |
| Pre-thrombolytic       | 4/192                            | 10/282                              | 0.34    |
| Previous angina        | 174/192                          | 233/282                             | 0.012   |
| Pre-PCI                | 49/192                           | 49/282                              | 0.032   |
| History of hypertension| 145/192                          | 207/282                             | 0.60    |
| Pre-CABG               | 6/192                            | 9/282                               | 0.96    |
| Taking antihypertensive drugs | 113/192 | 149/282                             | 0.19    |
| Arrhythmia             | 4/192                            | 11/282                              | 0.26    |
| HF                     | 0/192                            | 2/282                               | 0.15    |

(continued)
fraction (LVEF), high density lipoprotein (HDL), troponin I (TNI), lesion length ≥20 mm, previous angina, double vessel, pre-PCI, and number of stents observed between the two groups (p < 0.05). There was no significant difference between the two groups (p < 0.05). There was no significant difference between the groups in age, sex, body mass index (BMI), blood pressure, blood glucose, other biochemical indicators, hemoglobin A1c (HbA1c), smoking status, previous medical history, medication intake, and ACS composition ratio, the difference between early discharge and ordinary discharge. Furthermore, differences in chronic total occlusion (CTO), left main (LM) involvement, diameter of stent, in-stent restenosis, pre-CAD, pre-thrombolytic, history of hypertension, and pre-CABG were not statistically significant between the two groups. Differences in minor events at discharge and in MACCE at 30 days and 1 year of follow-up were not statistically significant between the two groups. Baseline demographics and procedure-related characteristics are shown in Tables 1 and 2, respectively.

| Variable                              | Early discharge | Ordinary discharge | P-value |
|---------------------------------------|-----------------|--------------------|---------|
|                                       | (<6 days n=192) | (≥6 days n=282)    |         |
| Previous cerebrovascular disease      | 28/192          | 43/282             | 0.84    |
| Previous peripheral blood vessels     | 6/192           | 9/282              | 0.97    |
| ALT (U/L)                             | 28±26           | 28±27              | 0.84    |
| AST (U/L)                             | 23±17           | 23±20              | 0.76    |
| Number of stents                      | 1.78±1.03       | 2.26±1.50          | 0.0001  |
| Diameter of stent                     | 2.90±0.43       | 2.80±0.45          | 0.11    |
| Hyperlipidemia                        | 37/192          | 50/282             | 0.67    |

Values are %, mean±SD, or median (interquartile range)

BMI, body mass index; HbAC1, hemoglobin A1c; UAP, unstable angina pectoris; NSTEMI, non-ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction; SBP, systolic pressure; DBP, diastolic blood pressure; LVEEDD, left ventricular end diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; HR, heart rate; Cr, creatinine; UA, uric acid; HDL, high density lipoprotein; TG, triglyceride, TC, total cholesterol; LDL, low-density lipoprotein; CRP, C-reactive protein; cTnI, sensitive cardiac troponin; CTO, chronic total occlusion; LMS, left main stem; BNP, brain natriuretic peptide; FU, follow-up; CABG, coronary artery bypass graft; CAD, coronary artery disease; PCI, percutaneous coronary intervention; HF, heart failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase

Table 3. Multivariate logistic analysis for predictors of early discharge

| Variable                              | Multivariable OR (95%CI) | P-value |
|---------------------------------------|--------------------------|---------|
| HDL-C                                 | 3.30 (1.42-7.90)         | 0.0036  |
| TNI                                   | 0.60 (0.32-0.92)         | 0.0073  |
| Number of stents                      | 0.70 (0.59-0.83)         | <0.001  |
| Previous angina                       | 2.27 (1.22-4.40)         | 0.0091  |

HDL-C, high density lipoprotein cholesterol; TNI, troponin I

Predictors of early discharge

In a multiple logistic regression model, the following variables were tested for their effect on time to discharge: age, sex, BMI, HbA1c, glucose, pre-PCI, hypertension, pre-CABG, hyperlipidemia, ex-smoker, HDL, C-reactive protein (CRP), hemoglobin (HGB), CTO, LVEF, TNI, and lesion length ≥20 mm, previous angina, double vessel, pre-PCI, and number of stents. These variables were selected as they are recognized as clinically important in defining low-risk patients and were found to have a significant impact on early discharge.
in univariate analysis. HDL, TNI, number of stents, and previous angina were found to be independent predictors of early discharge, and their odds ratios (OR) in multiple logistic regression analysis are shown in Table 3.

**Mortality outcomes**

At discharge, minor events were reported in 10 patients in the early discharge group and 20 patients in the ordinary discharge group. At the 30-day follow-up, MACCE events were reported in 6 patients in the early discharge group and 4 patients in the ordinary discharge group. At the 1-year follow-up, events were reported in 18 patients in the early discharge group and 30 patients in the ordinary discharge group. The incidence of MACCE was not significantly increased in the early discharge groups at either 30 days or 1 year, and there were no significant differences in the incidence of MACCE between the two groups.

**Impact of the hospital stay on outcomes**

Figure 1 shows the impact of the hospital stay on outcomes of patients undergoing PCI in the early and ordinary discharge groups. Kaplan–Meier analysis showed a similar prognosis between the groups at 30 days (log rank \( P=0.19 \)).

**Discussion**

The incidence of coronary heart disease is significantly increased among patients with DM, and is closely related to the severity of coronary atherosclerosis.\(^{16–18}\) Because of the diffuse lesions observed in this patient population, distal lesions are more numerous, degree of atherosclerosis and rate of restenosis is higher, and the coronary diastolic reserve is poorer than in patients without DM. Thus, the number of patients undergoing PCI is significantly increased, the length of hospital stay is increased, and the total hospitalization expenses are significantly increased.\(^{19,20}\)

With advancements in vascular access technology, scaffolding technology, and antiplatelet pharmacology, the discharge time after PCI has been greatly reduced.\(^{21}\) Multiple clinical studies have demonstrated the safety of early and day-to-date discharge in patients with selective PCI,\(^{22–25}\) and this strategy was deemed acceptable in the 2018 SCAI Expert Consensus Document on Hospitalization Time after Percutaneous Coronary Intervention (PCI) Promotion;\(^{26}\) furthermore, this strategy prevents unnecessary hospitalization and is thus cost-effective for the Chinese healthcare system. These guidelines clearly state that these recommendations are intended to support reasonable clinical decisions for
postoperative hospital stays in a wide range of patients undergoing PCI, rather than specifying specific observation periods for individual patients.

**Time limit for early discharge**

A recent large observational study of 33,920 patients from the PCI registry provided insights into post-PCI discharge patterns and related outcomes. Hospital stay (LOS) was divided into short-term (up to 3 days), medium-term (4–5 days) and long-term (>5 days). There were no significant differences in 3-day mortality or MACE between the short- and medium-term LOS groups. The study found that diabetes uncomplicated by coronary heart disease was the main factor influencing LOS, and that patients without diabetes were discharged earlier.27 All patients in our study had DM, so the length of hospital stay in our study population was significantly longer than that in the previous study, and no patients were discharged in less than 3 days (median of 6 days). All patients in the present study had ACS, and the maximum UAP share was 82.1% and mild non-ST-segment elevation ACS (NSTEACS) was 0.4%, while STEMI patients comprised 13.6% of those undergoing direct PCI (PPCI). The degree of coronary atherosclerosis is an important consideration in patients with diabetes. Angiography showed that the incidence of multi-vessel disease, diffuse stenosis, small vessel disease, high atherosclerotic plaque load, small vascular development, poor development of collateral circulation, and serious microcirculatory dysfunction was increased in this patient population. Patients with DM have a higher clinical risk of acute ischemic and hemorrhagic events.28 All patients in the present study had DM, and the average postoperative hospitalization stay after PCI was 6 days, longer than the SCAI expert consensus in 2018.26 We analyzed the reasons for multiple hospitalizations, massive stent implantation, and postoperative hypercoagulability requiring 5–7 days of low-molecular-weight heparin therapy.

**Early discharge predictors**

Our findings showed that HDL level, TNI, number of stents, and previous angina were independent predictors of whether patients with DM could be discharged early. These factors are associated with the overall burden of DM with cardiovascular disease (CVD) and reflect the recurrence or progression of underlying CAD. High density lipoprotein (HDL) is negatively correlated with the presence and development of CAD.30 HDL-cholesterol is the only standardized and repeatable parameter that can be used to estimate the plasma concentrations of these lipoproteins. HDL exerts a variety of anti-atherosclerotic effects, and evidence showing that HDL has protective effects in atherosclerosis is increasing31,32. Previous studies have shown that DM is associated with an increased burden of CAD, and that low HDL is an independent predictor of CAD progression33. Our research further indicates that HDL level is associated with the severity of coronary artery lesions and early discharge from hospital after PCI. It has been established that cardiac troponin (cTnI) significantly improves the early diagnosis of ACS34, and that sensitive cTnI detection is of great significance for early diagnosis of ACS patients and prediction of long-term prognosis35. Our research supports this observation, and can predict whether patients can be discharged early, the increase in cTnI is delayed, and the patient’s condition is complicated.

In our study, high-risk patients were identified a priori as having LM involvement, CTO, double vessels, and pre-PCI. Previous studies have reported multiple stent complications in patients with diabetes and severe ACS, complicated lesions, and multiple...
Anticoagulation requires 5–7 days of low-molecular-weight heparin therapy, thus prolonging the hospital stay. In patients with DM and a history of angina pectoris, coronary atherosclerosis is often more diffuse than in patients without DM, and features longer lesions, smaller vascular lumens, and larger plaques. In addition, vascular endothelial function is impaired in patients with diabetes, as is platelet systolic function, and these factors can contribute to the development of ACS as well as to more complex lesions and complications, and prolonged hospital stays. Therefore, previous history of angina pectoris is an independent predictor of early discharge after PCI.

30-day assessment
The assessment of early discharge safety has been extensively studied in recent years. In a 2017 systematic review and meta-analysis of safety and cost, data from 12 randomized controlled trials in 2962 patients were analyzed. At the follow-up time of 30 days in patients with stable angina, the rate of re-hospitalization of patients with ACS increased, and the early discharge duration was shorter (<72 hours), although no specific analysis of the reasons for re-hospitalization was reported.

In addition, a PCI medical cost and safety study in the United States examined data from 206,869 inpatients discharged after PCI and re-admitted within 30 days of discharge. A total of 24,889 patients (12%) received treatment again within 30 days. The most common cause of re-admission was non-specific chest pain, although the majority of readmissions were the result of low-risk chest pain that did not require any intervention.

It has been established that patients with coronary heart disease and diabetes have a higher risk of coronary dissection, stent thrombosis, and in-stent restenosis when undergoing coronary revascularization, and that these events are prone to occur within 30 days after surgery. In the present study, care was taken to assess risks and to select appropriate patients for early discharge based on HDL level, TNI level, number of interventional stents, and previous angina. No safety concerns were associated with early discharge within 6 days of surgery. There was no increase in adverse cardiovascular events during the 30-day follow-up period in either group, and no significant difference in adverse cardiovascular events between the two groups.

Cost analysis and social implications
Rapid increases in medical expenses are a major healthcare consideration, and are of significant concern to society and governments. The results of this study can support the evaluation of PCI from the perspective of health economics and medical outcomes. CVD is associated with the highest economic costs compared with other diseases. According to the 2012 National Healthcare Cost and Utilization Project statistics, the mean hospital charge for a vascular or cardiac surgery or procedure in 2012 was USD78,897; cardiac revascularization cost USD149,480 and percutaneous interventions cost approximately USD70,027. CVD has higher costs than any other diagnostic group. For a consecutive cohort of 5,306 patients undergoing PCI in China in 2010, total hospital costs were RMB57,900 for transradial intervention and RMB67,418 for transfemoral intervention. The present study showed that the total cost of hospitalization for PCI following early discharge was significantly lower than that following ordinary discharge (RMB50,983 versus RMB65,750, a reduction of RMB14,767), highlighting the benefit of early discharge. Although we found no additional clinical benefit compared with regular discharge during the first 30 days after surgery, early
discharge appears to be more cost-effective and may have a significant benefit in the care of patients with DM and resource allocation for coronary revascularization protocols in clinical settings. After PCI, the hospital can effectively reduce costs by reducing the average hospital stay and unnecessary hospitalization time while maintaining patient prognosis.

Limitations
This study had a number of limitations. First, although the data used in this study were from a cardiac center with a large number of patients undergoing PCI, this was a single-center observational study. Second, the follow-up time was relatively short and the status of patients after 3 years was unknown, so the long-term risk of revascularization and medical costs may have been underestimated in patients with DM complicated with CAD. Finally, the limited sample size means that further research is needed to confirm our findings.

Availability of data and materials
The data and materials used in this study are available upon reasonable request from the corresponding author once the paper has been published.

Authors’ contribution
Shihong Li and Tao Sun participated in study design, data analysis, and the drafting of the manuscript. Zhizhong Li was involved in the conduct of the study and data analysis.

Declaration of conflicting interests
The authors declare that there is no conflict of interest.

Funding
This study was supported by funding from the Precision Medicine of Cardiovascular Disease (PXM2019-014226-000023).

ORCID iD
Tao Sun https://orcid.org/0000-0002-5504-1817

References
1. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in china, 1990—2010: findings form the Global Burden of Disease Study 2010. *Lancet* 2013; 381: 1987–2015.
2. Shaw JE, Sicree RA and Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010; 87: 4–14.
3. Amarasekara P, de Silva A, Swarnamali H, et al. Knowledge, attitudes, and practices on lifestyle and cardiovascular risk factors among metabolic syndrome patients in an urban tertiary care institute in Sri Lanka. *Asia Pac J Public Health* 2016; 28: 32S–40S.
4. Liu MB, Wang W and Zhou MG. Trend analysis on the mortality of cardiovascular diseases from 2004 to 2010 in China. *Zhonghua Liu Xing Bing Xue Za Zhi* 2013; 34: 985–988.
5. Wang W, McGreevey WP, Fu C, et al. Type 2 diabetes mellitus in China: a preventable economic burden. *Am J Manag Care* 2009; 15: 593–601.
6. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2012; 60: 2564–2603.
7. 2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-st-elevation myocardial infarction (updating the 2007 guideline and replacing
8. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of st-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. *Circulation* 2013; 127: 529–555.

9. Wang BH, Wang H, Yang CZ, et al. Survey of the readiness for hospital discharge and its influencing factors among coronary heart disease patients. *Chin J Nurs* 2017; 52: 138–143.

10. Yuan X, Zhang H, Zheng Z, et al. Trends in mortality and major complications for patients undergoing coronary artery bypass grafting among urban teaching hospitals in China: 2004 to 2013. *Eur Heart J Qual Care Clin Outcomes* 2017; 3: 312–318.

11. Wang M, Moran AE, Liu J, et al. Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. *Circ Cardiovasc Qual Outcomes* 2014; 7: 78–85.

12. Zhang Q, Zhao D, Xie W, et al. Recent trends in hospitalization for acute myocardial infarction in Beijing: increasing overall burden and a transition from ST-segment elevation to non-ST-segment elevation myocardial infarction in a population-based study. *Medicine (Baltimore)* 2016; 95: e2677.

13. American Diabetes Association. Standards of medical care in diabetes —2014. Diabetes Care. 2014;37(suppl 1):S14–S80.

14. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *JAMA*. 2003;289:2560–2572.

15. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 suppl 2):S1–S45.

16. Wang H, Tang Z, Li X, et al. Angiographic evaluation of the effects of glucose metabolic status on progression of coronary artery lesions in patients with coronary artery disease. *J Diabetes* 2014; 6: 541–546.

17. Saleh N, Petursson P, Lagerqvist B, et al. Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment. *Diabetologia* 2012; 55: 2109–2117.

18. Rosner GF, Kirtane AJ, Genereux P, et al. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. *Circulation* 2012; 125: 2613–2620.

19. Garcia S, Sandoval Y, Roukoz H, et al. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. *J Am Coll Cardiol* 2013; 62: 1421–1431.

20. Zhang M, Mao J, Tuerdi A, et al. The constellation of macrovascular risk factors in early onset T2DM: a cross-sectional study in Xinjiang Province, China. *J Diabetes Res* 2018; 3: 3089317.

21. Chambers CE, Dehmer GJ, Cox DA, et al. Society for Cardiovascular Angiography and Interventions. Defining the length of stay following percutaneous coronary intervention: An expert consensus document from the Society for Cardiovascular Angiography and Interventions. *Catheter Cardiovasc Interv* 2009;73:847–858.

22. Amin AP, Patterson M, House JA, et al. Costs associated with access site and same-day discharge among medicare beneficiaries undergoing percutaneous coronary intervention: an evaluation of the current percutaneous coronary intervention care pathways in the United States. *JACC Cardiovasc Interv* 2017; 10: 342–351.

23. Jolly SS, Amiani S, Hamon M, et al. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic
review and meta-analysis of randomized trials. Am Heart J 2009; 157: 132–140.

24. Heyde GS, Koch KT, de Winter RJ, et al. Randomized trial comparing same-day discharge with overnight hospital stay after percutaneous coronary intervention: results of the Elective PCI in Outpatient Study (EPOS). Circulation 2007; 115: 2299–306.

25. Jabara R, Gadesam R, Pendyala L, et al. Ambulatory discharge after transradial coronary intervention: preliminary US single-center experience (Same-day TransRadial Intervention and Discharge Evaluation, the STRIDE Study). Am Heart J 2008; 156: 1141–1146.

26. Seto AH, Shroff A, Abu-Fadel M, et al. Length of stay following percutaneous coronary intervention: an expert consensus document update from the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interv 2018; 24: 1–15.

27. Swaminathan RV, Rao SV, McCoy LA, et al. Hospital length of stay and clinical outcomes in older STEMI patients after primary PCI: a report from the National Cardiovascular Data Registry. J Am Coll Cardiol 2015; 65: 1161–1171.

28. Colwell JA and Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181–2188.

29. Kociol RD, Lopes RD, Clare R, Thomas L, Mehta RH, Kaul P, Pieper KS, Hochman JS, Weaver WD, Armstrong PW, Granger CB, Patel MR. International variation in and factors associated with hospital readmission after myocardial infarction. JAMA 2012;307:66–74.

30. Gordon DJ, Rifkind BM. High-density lipoprotein – the clinical implications of recent studies. N Engl J Med.1989;321:1311–1316.

31. Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J 1983; 106: 1191–1200.

32. Epand RM, Stafford A, Leon B, et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 1994; 14: 1775–1783.

33. Kaneko H, Yajima J, Oikawa Y, et al. Long-term incidence and prognostic factors of the progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention. Heart Vessels 2014; 29: 437–442.

34. Tan JWC, Lam CSP, Kasim SS, et al. Asia-Pacific consensus statement on the optimal use of high-sensitivity troponin assays in acute coronary syndromes diagnosis: focus on hs-TnI. Heart Asia 2017; 9: 81–87.

35. Gravning JF, Smedsrud MK, Omland T, et al. Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis. Am Heart J 2013; 5: 716–724.

36. Windecker S, Kolh P, Jean-Philippe C, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal Advance Access 2014; 37: 2541–2619. https://doi.org/10.1093/eurheartj/ehu278

37. Jaguszewski M, Radovanovic D, Nallamothu BK, et al. Multivessel versus culprit vessel percutaneous coronary intervention in ST-elevation myocardial infarction: is more worse? EuroIntervention 2013; 9: 909–915.

38. Buccheri S and Capodanno D. Coronary revascularization strategies in patients with multivessel disease: is it all about diabetes? Cardiovasc Diagn Ther 2017; 7: E1–E3.

39. Rask-Madsen C and King GL. Mechanisms of disease:endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007; 3: 46–56.

40. Abdelnoor M, Andersen JG, Arnesen H, et al. Early discharge compared with ordinary discharge after percutaneous coronary intervention – a systematic review and meta-analysis of safety and cost. Vase Health Risk Manag 2017; 13: 102–109.

41. Tripathi A, Abbott JD, Fonarow GC, et al. Thirty-day readmission rate and costs after percutaneous coronary intervention in the United States a national readmission database analysis. Circ Cardiovasc Interv 2017; 10: e005925.

42. Naganuma T, Latib A, Sgueglia GA, et al. A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study. Int J Cardiol 2015; 184: 17–21.
43. Sinha N, Rai H, Cassese S, et al. Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients. *Coron Artery Dis* 2016; 27: 385–390.

44. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS. Executive Summary: Heart Disease and Stroke Statistics–2016 Update: A report from the American Heart Association. *Circulation* 2016; 133:447–454.

45. Jin C, Li W, Qiao SB, et al. Costs and benefits associated with transradial versus transfemoral percutaneous coronary intervention in China. *J Am Heart Assoc* 2016; 5: pii: e002684.